Nomic Bio
YC W20Montreal, CA · Founded 2017 · 24 employees · 4 known investors
Nomic Bio develops an immunoassay platform that enables drug discovery scientists to profile hundreds of proteins with higher throughput and lower cost than conventional methods. The company is initially targeting high-throughput screening groups at pharmaceutical and biotech firms.
Founders & leadership· Y Combinator alumni (W20)
Investors · 4
In the news
- Nomic Bio secures $42 million Series B to expand startup’s protein mapping platform | BetaKitbetakit.com · 2024
- Nomic Bio: Protein Profiling Company Raises $42 Million (Series B)pulse2.com · 2024
- Nomic Bio secures $42M Series B | Private Capital Journalprivatecapitaljournal.com · 2024
- Nomic Raises $42M in Series B Fundingfinsmes.com · 2024
- Nomic Closes $17 Million Series A to Develop and Commercialize the World’s Highest Throughput Proteomic Platformbusinesswire.com · 2021
- Rebranded Nomic Bio raises $17 million to fuel development of protein-measuring platform | BetaKitbetakit.com · 2021
- Nomic collects $17M to advance its automated, high-throughput ELISA platform | FierceBiotechfiercebiotech.com · 2021